Greenland Mines Ltd (GRML, formerly Klotho Neurosciences Inc., renamed effective March 11, 2026) is a pre-revenue stage biotech/mining hybrid entity that completed a SPAC reverse merger in June 2024 and a subsequent merger with Greenland Mines Corp. (a mineral properties holding company) in March 2026 as a subsequent event. Under the liquidation lens at December 31, 2025, recovery to equity is marginally positive but structurally fragile. Total assets of $9.6M are dominated by cash ($7.2M, 100% recoverable) and intangible assets ($2.3M, 0% recoverable under liquidation haircuts). Applying standard haircuts: cash recovers at $7.2M; prepaid expenses ($0.12M) recover near zero; intangibles (medical licenses and patents carried at $2.3M, all pre-revenue and unproven) recover $0. Total haircut-adjusted asset value is approximately $7.2M. Total liabilities at face value are $0.13M (accounts payable and accrued liabilities $77K plus warrant liability $53K), yielding an estimated net liquidation recovery to equity of approximately $7.1M—consistent with MFFAIS CLV/LLV/OLV of $7.1M. This is positive only because the balance sheet is nearly all cash following aggressive warrant exercise financing ($11.4M gross proceeds from ~11M warrants exercised in 2025) and convertible note proceeds ($2.15M new issuances), partially offset by $5.9M operating cash burn. The company burned approximately $5.9M in operating cash in FY2025 against a net loss of $10.6M (the difference attributable to $2.3M paid-in-kind interest, $1.6M stock compensation, and other non-cash items). The intangible asset base ($2.3M carrying value: four anti-cancer drug licenses from Encore at $1.3M, various biosimilar licenses at $0.7M, Heidelberg University non-exclusive license at $0.18M, needleless syringe license at $26K, patents at $48K) carries zero liquidation value—none are in use, revenue is nil, and the company explicitly states commercial utilization is expected no earlier than 2026. The Teleost Biopharmaceutic license was already impaired and written off in 2024 ($10K). The primary change versus the prior period (Q3 2025 10-Q, September 30, 2025) is the material increase in cash from approximately $0.1M at December 31, 2024 to $7.2M at December 31, 2025, driven by $13.0M net financing inflows. The liability stack was largely cleared: the Austria Capital convertible note ($1.2M principal) was settled via $650K conversion and $550K cash; the 3i institutional investor notes ($823K principal plus $58K interest) were converted into shares; all Red Road Holdings notes were repaid in cash. As of December 31, 2025, total liabilities are $130K, an 87% reduction from the December 31, 2024 balance. The subsequent-event Greenland Mines merger introduces a mineral property interest (80% of Major Precious Greenland A/S, owner of the Skaergaard Project in Greenland with a 2022 NI 43-101 resource of 364M tonnes) but this is not reflected on the December 31, 2025 balance sheet and carries no XBRL-tagged fair value. The filing does not separately tag the Skaergaard mineral property or the 80% interest in XBRL; it is described only in the subsequent events narrative. The company is also under Nasdaq minimum bid price deficiency as of September 19, 2025, with a compliance deadline extended to September 14, 2026, representing a live delisting risk that would not affect liquidation value but would affect any going-concern premium. Corporate income tax returns are noted as delinquent; actual NOL carryforward amounts may differ from estimates.
▼ Community Notes